Premium
57 Co‐Bleomycin imaging study of tumors of the head and neck.
Author(s) -
SawasDimopoulou Christine,
Pantazopoulos Panos,
Dokianakis George,
Apostolopoulos Nicolas,
Papafrangou Constantine
Publication year - 1978
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1288/00005537-197806000-00013
Subject(s) - larynx , medicine , bleomycin , head and neck , pharynx , nuclear medicine , scintigraphy , nose , radiology , pathology , surgery , chemotherapy
Abstract 57 Co‐Bleomycin ( 57 Co‐BLM) was used to visualize malignancies of the head and neck because it does not present the disadvantages of many other radiopharmaceuticals. In a series of 21 patients with 9 control subjects and 12 cases of tumors. 57 Co‐BLM showed a high and rapid uptake in primary site and metastases of malignant tumors of various histologic types, but not in benign tumors such as angiofibromas. Compared to 67 Ga‐citrate. 57 Co‐BLM has many advantages for tumor imaging in the areas of nose, pharynx and larynx: No background activity due to the concentration of 57 Co‐BLM in normal structures of the head and neck has ever been observed, as opposed to what happens with 67 Ga‐citrate. Furthermore, the blood clearance of 57 Co‐BLM is much more rapid than that of 67 Ga‐citrate, so that an early study may be performed in a 6‐24 hr. interval instead of 48–72 hr. with 67 Ga‐citrate. 57 Co‐BLM scintigraphy is an easy, non‐invasive and sensible diagnostic technique in determining the extent of malignant tumors in ORL patients.